Swapnroop Drugs & Pharmaceuticals offers Tiludronic Acid as a pharmaceutical active ingredient for applications related to bone metabolism and bisphosphonate drug development. Tiludronic Acid, also known as Tiludronate, is a synthetic bisphosphonate compound belonging to the class of drugs that affect bone structure and mineralization.
Tiludronic Acid is associated with the treatment of bone disorders, particularly Paget's disease of bone. It acts primarily by inhibiting osteoclast-mediated bone resorption, thereby reducing excessive breakdown of mineralized bone tissue.
The compound is chemically identified as [(4-chlorophenyl)sulfanyl-phosphonomethyl]phosphonic acid and contains two phosphonic acid groups. PubChem lists Tiludronic Acid under CAS No. 89987-06-4 with molecular formula C7H9ClO6P2S and molecular weight 318.61 g/mol.
Tiludronic Acid is a nitrogen-free bisphosphonate. Unlike nitrogen-containing bisphosphonates, its molecular structure contains a chlorophenylthio substituent attached to a methylene bisphosphonate group.
Tiludronic Acid is also known as Tiludronate and has been assigned ATC code M05BA05. The compound is classified within the bisphosphonate group of medicines affecting bone structure and mineralization.
| Parameter | Details |
|---|---|
| Product Name | Tiludronic Acid |
| Synonyms | Tiludronate, Tiludronic Acid |
| CAS No. | 89987-06-4 |
| Molecular Formula | C7H9ClO6P2S |
| Molecular Weight | 318.61 g/mol |
| IUPAC Name | [(4-chlorophenyl)sulfanyl-phosphonomethyl]phosphonic acid |
| Chemical Class | Bisphosphonate |
| Drug Class | Bone metabolism / Bisphosphonate |
| ATC Code | M05BA05 |
| PubChem CID | 60937 |
| Appearance | White to off-white powder |
| Physical Form | Powder |
| Chirality | Achiral |
| Target/Action | Inhibition of osteoclast-mediated bone resorption |
The chemical identity, formula, molecular weight, CAS number and PubChem CID are documented by PubChem.
Tiludronic Acid is a bisphosphonate used in pharmaceutical applications involving disorders of bone remodeling. Its established therapeutic association is with Paget's disease of bone (osteitis deformans).
Its pharmacological activity is primarily associated with suppression of osteoclastic bone resorption. By reducing excessive osteoclast activity, bisphosphonates such as tiludronate can help reduce abnormal bone turnover.
Tiludronic Acid acts primarily on bone tissue and inhibits osteoclastic activity. This reduces the processes responsible for resorption of the mineralized bone matrix.
As a non-nitrogen-containing bisphosphonate, Tiludronic Acid differs structurally and mechanistically from later-generation nitrogen-containing bisphosphonates.
As a small-molecule bisphosphonate, Tiludronic Acid can be characterized using conventional pharmaceutical analytical techniques.
Typical quality-control testing may include:
The applicable release specifications should be established according to the manufacturer's approved specification, customer requirements and the applicable regulatory standard.
A UK veterinary regulatory assessment notes that disodium tiludronate is an established active substance but is not described in a pharmacopoeial monograph in that context; the active-substance specification was therefore controlled through an Active Substance Master File (ASMF).
Swapnroop Drugs & Pharmaceuticals focuses on pharmaceutical active ingredients with emphasis on quality, analytical characterization, documentation and controlled manufacturing practices.
Tiludronic Acid can be supplied for pharmaceutical development and manufacturing applications according to agreed product specifications and applicable quality requirements.
Tiludronic Acid should be packaged in suitable, tightly closed pharmaceutical-grade containers that protect the material from moisture and contamination.
Recommended storage conditions should follow the approved product specification and stability data. Published chemical data describe Tiludronic Acid as a powder and report room-temperature storage conditions; specific commercial storage requirements should be confirmed against the applicable batch specification.
Depending on the grade and customer requirements, documentation may include:
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.10% |
| Heavy Metals | NMT 20 ppm |
| pH (1% Solution) | 6.0–8.0 |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 2.0% |
| Water Content | NMT 5.0% |